Tachycardia-induced myocardial ischemia and diastolic dysfunction potentiate secretion of ANP, not BNP, in hypertrophic cardiomyopathy.

about

Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy

P2860

Q24197872-5BD5BE10-3201-4BC7-869E-BEC2632C6FC0

P2860

Tachycardia-induced myocardial ischemia and diastolic dysfunction potentiate secretion of ANP, not BNP, in hypertrophic cardiomyopathy.

Item

http://www.wikidata.org/entity/Q46711295

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Tachycardia-induced myocardial ...... n hypertrophic cardiomyopathy.

@en

Tachycardia-induced myocardial ...... n hypertrophic cardiomyopathy.

@nl

type

Item

label

Tachycardia-induced myocardial ...... n hypertrophic cardiomyopathy.

@en

Tachycardia-induced myocardial ...... n hypertrophic cardiomyopathy.

@nl

prefLabel

Tachycardia-induced myocardial ...... n hypertrophic cardiomyopathy.

@en

Tachycardia-induced myocardial ...... n hypertrophic cardiomyopathy.

@nl

P1476

Tachycardia-induced myocardial ...... n hypertrophic cardiomyopathy.

@en

P2093

Kenjiro Kikuchi

http://www.w3.org/2001/XMLSchema#string

Naoyuki Hasebe

http://www.w3.org/2001/XMLSchema#string

Shinsuke Kido

http://www.w3.org/2001/XMLSchema#string

Yoshinao Ishii

http://www.w3.org/2001/XMLSchema#string

P2860

Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy.

Predictors of sudden cardiac death in hypertrophic cardiomyopathy.

Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide.

Left ventricular diastolic dysfunction as a cause of congestive heart failure. Mechanisms and management.

Natriuretic peptides and cyclic guanosine 3',5'-monophosphate in asymptomatic and symptomatic left ventricular dysfunction.

Recognition and treatment of left ventricular diastolic dysfunction.

Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method.

Hypertrophic cardiomyopathy. Clinical spectrum and treatment.

26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse.

Inhaled nitric oxide modifies left ventricular diastolic stress in the presence of vasoactive agents in heart failure.

P304

H1064-70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPHEART.00110.2005

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

290

http://www.w3.org/2001/XMLSchema#string

P577

2005-09-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7591966

http://www.w3.org/2001/XMLSchema#string

P698

16172169

http://www.w3.org/2001/XMLSchema#string

P921

diastole

Tachycardia-induced myocardial ischemia and diastolic dysfunction potentiate secretion of ANP, not BNP, in hypertrophic cardiomyopathy.

about

P2860

P2860

Tachycardia-induced myocardial ischemia and diastolic dysfunction potentiate secretion of ANP, not BNP, in hypertrophic cardiomyopathy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921